Tlr4 (Toll Like Receptor 4) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Toll-Like Receptor 4 (TLR4 is a pattern recognition receptor of the innate immune system that plays a critical role in detecting
pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) [1]. In the [central nervous system, TLR4 is primarily expressed on
[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--/cell-types/microglia, making it uniquely positioned to link peripheral infection, [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX--, and
[neurodegeneration)/diseases) [5].
¶ Molecular Structure and Signaling Pathways
TLR4 is a type I transmembrane protein composed of three major domains [6]:
- Extracellular domain: Contains leucine-rich repeat (LRR) motifs that mediate ligand recognition
- Transmembrane domain: Single helix anchoring the receptor in the plasma membrane
- Intracellular Toll/IL-1 receptor (TIR) domain: Initiates downstream signaling cascades
The extracellular domain undergoes conformational changes upon ligand binding, enabling dimerization and recruitment of adaptor [proteins[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/proteins [7]. This structural rearrangement is critical for
signal transduction and distinguishes TLR4 from other pattern recognition receptors.
Upon ligand binding, TLR4 recruits the adaptor protein MyD88 (Myeloid Differentiation Primary Response 88) through homophilic TIR domain interactions [8]. This initiates a cascade of events:
- MyD88 recruitment: MyD88 associates with TLR4 via its TIR domain
- Kinase activation: MyD88 recruits IRAK family kinases (IRAK4, IRAK1, IRAK2)
- TAK1 activation: The IRAK complex activates TAK1 (Transforming Growth Factor-beta-Activated Kinase 1)
- NF-κB] and MAPK activation: TAK1 phosphorylates IKK complex and MAP kinases, leading to [NF-κB[/entities/[nf-kb[/entities/[nf-kb[/entities/[nf-kb[/entities/[nf-kb--TEMP--/entities)--FIX-- activation and inflammatory gene transcription [9]
The MyD88-dependent pathway primarily drives pro-inflammatory cytokine production, including [tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) [10].
TLR4 also signals through the MyD88-independent (TRIF-dependent) pathway [11]:
- TRIF recruitment: TLR4 recruits TRIF (TIR-Domain-Containing Adaptor-Inducing Interferon-β) adaptor protein
- TBK1 activation: TRIF activates TBK1 (TANK-binding kinase 1)
- IRF3 activation: TBK1 phosphorylates IRF3 (Interferon Regulatory Factor 3)
- Type I interferon production: IRF3 translocation to the nucleus induces interferon-beta expression [12]
The TRIF pathway contributes to antiviral responses and can modulate [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX-- in chronic neurological conditions.
TLR4 is highly expressed in [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--" data-ref-url="https://doi.org/10.4049/jimmunol.1102711" data-ref-title="Doyle et al. Toll-like receptor 4 contributes to microglial activation and amyloid pathology (2011)" data-ref-authors="Doyle et al" data-ref-year="2011" data-ref-journal="Toll-like receptor 4 contributes to microglial activation and amyloid pathology (2011)" data-ref-doi="10.4049/jimmunol.1102711" title="Doyle et al. Toll-like receptor 4 contributes to microglial activation and amyloid pathology (2011)"><a href="#references" class="ref-link" data-ref-number="16" data-ref-text="oligodendrocytes"#references">[17].
TLR4 directly recognizes [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- aggregates as a DAMP [18]. This interaction:
- Facilitates amyloid clearance: TLR4 activation enhances [microglial phagocytosis[/mechanisms/[microglial-phagocytosis[/mechanisms/[microglial-phagocytosis[/mechanisms/[microglial-phagocytosis[/mechanisms/[microglial-phagocytosis--TEMP--/mechanisms)--FIX-- of [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX--
- Triggers inflammation: [Amyloid]-TLR4 binding activates [NF-κB[/entities/[nf-kb[/entities/[nf-kb[/entities/[nf-kb[/entities/[nf-kb--TEMP--/entities)--FIX-- and pro-inflammatory pathways
- Drives chronic activation: Persistent amyloid presence leads to microglial dysregulation and burnout [19]
The dual role of TLR4 in both clearing and promoting inflammation around amyloid plaques represents a key therapeutic challenge.
Polymorphisms in the TLR4 gene influence [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- risk [20]:
- Asp299Gly polymorphism: Associated with decreased risk of AD in some populations
- Thr399Ile polymorphism: May affect TLR4 signaling efficiency and inflammation
- Haplotype effects: Combined polymorphisms modulate disease progression
These genetic findings support TLR4's pathogenic role in AD and suggest targeting this pathway may have therapeutic benefit.
TLR4 represents a promising therapeutic target for [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- [21]:
- Antagonists: Small molecule inhibitors blocking TLR4 activation
- Neutralizing antibodies: Anti-TLR4 antibodies preventing ligand binding
- Signal transduction inhibitors: Compounds targeting downstream kinases (TAK1, TBK1)
- Natural compounds: Curcumin, resveratrol and other anti-inflammatory agents modulating TLR4 signaling
Clinical trials exploring TLR4 modulation in AD are ongoing, though challenges remain in achieving sufficient brain penetration and specificity.
In [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, TLR4 contributes to neuroinflammation through [22]:
-
Recognition of [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX-- aggregates as DAMPs
-
Activation of [microglia[/[multiple[/[multiple[/[multiple[/[multiple[/[multiple[/[multiple[/[multiple[/multiple sclerosis and experimental autoimmune encephalomyelitis (EAE) [24]:
-
TLR4 contributes to [demyelination[/mechanisms/[demyelination[/mechanisms/[demyelination[/mechanisms/[demyelination[/mechanisms/[demyelination--TEMP--/mechanisms)--FIX-- and lesion formation
-
Peripheral immune cell infiltration requires TLR4 signaling
-
Modulation shows promise in preclinical models
¶ Stroke and Brain Injury
TLR4 plays complex roles in [brain injury [25]:
- Acute phase: Mediates inflammatory response to tissue damage
- Secondary injury: Contributes to [excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity--TEMP--/entities)--FIX-- and [Blood-Brain Barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- disruption
- Repair phase: Necessary for debris clearance and tissue remodeling
- Therapeutic window: Timing of TLR4 modulation critical for outcome
TLR4 is widely expressed on peripheral immune cells [26]:
- Macrophages: Primary responders to bacterial infection
- Dendritic cells: Bridge innate and [adaptive immunity[/mechanisms/[adaptive-immunity[/mechanisms/[adaptive-immunity[/mechanisms/[adaptive-immunity[/mechanisms/[adaptive-immunity--TEMP--/mechanisms)--FIX--
- B cells: Participate in antibody responses
- T cells: Modulate adaptive immune responses
TLR4 mediates communication between peripheral inflammation and the [brain [27]:
- Systemic inflammation: Peripheral LPS elevates CNS TLR4 expression
- Cytokine signaling: Pro-inflammatory cytokines access brain through circumventricular organs
- Vagal signaling: Vagus nerve transmits inflammatory signals to [brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem--TEMP--/brain-regions)--FIX--
- [blood-brain barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX--: TLR4 activation affects barrier permeability
This peripheral-central immune axis has implications for infection-associated [neurodegeneration[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases and psychiatric symptoms.
TLR4 expression and signaling serve as potential biomarkers [28]:
- CSF TLR4: Elevated in AD, PD, and ALS patients
- Microglial markers: TLR4 correlates with disease severity
- Therapeutic monitoring: TLR4 modulation may predict treatment response
TLR4-based diagnostic approaches under development [29]:
- Peripheral blood mononuclear cells: TLR4 expression distinguishes disease states
- Soluble TLR4: May serve as a biomarker in cerebrospinal fluid
- Genetic testing: TLR4 polymorphisms for risk assessment
Toll-Like Receptor 4 (TLR4 is a critical pattern recognition receptor linking innate immunity to neuroinflammation in the [central nervous
system. Through its ability to recognize both pathogen-derived and endogenous danger signals, TLR4 serves as a sentinel for [brain injury
and infection. In [neurodegenerative diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases, TLR4-mediated microglial activation contributes substantially to chronic
neuroinflammation and neuronal dysfunction. While acute TLR4 activation plays protective roles in debris clearance and repair, persistent
activation promotes [neurodegeneration[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases. The central role of TLR4 in disease pathogenesis makes it an attractive therapeutic
target, though achieving selective modulation without compromising host defense remains challenging. Understanding the complex biology of
TLR4 in the [brain continues to inform strategies for treating [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, and other
neurological conditions characterized by [neuroinflammation.
The study of Tlr4 (Toll Like Receptor 4) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [/diseases/alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--
- [/mechanisms/amyloid-hypothesis[/mechanisms/[amyloid-hypothesis[/mechanisms/[amyloid-hypothesis[/mechanisms/[amyloid-hypothesis[/mechanisms/[amyloid-hypothesis--TEMP--/mechanisms)--FIX--
- [/mechanisms/tau-pathology[/mechanisms/[tau-pathology[/mechanisms/[tau-pathology[/mechanisms/[tau-pathology[/mechanisms/[tau-pathology--TEMP--/mechanisms)--FIX--
- [/diseases/parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--
- [/mechanisms/alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein--TEMP--/mechanisms)--FIX--
- 1038/nri2565](https://doi.org/10.1038/nri2565)
-
- 1016/S1474-4422(15](https://doi.org/10.1016/S1474-4422(15)
- 1016/j.cell.2010.02.016](https://doi.org/10.1016/j.cell.2010.02.016)
- 1093/brain/awl249](https://doi.org/10.1093/brain/awl249)
- 1523/JNEUROSCI.3348-09.2009](https://doi.org/10.1523/JNEUROSCI.3348-09.2009)
- Minoretti P, Gazzaruso C, V用意 D, et al. Effect of the functional toll-like receptor 4 Asp299Gly polymorphism on susceptibility to and severity of [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--. Mol Med Rep. 2006;3(5]:803-807.
- 1186/1742-2094-8-92](https://doi.org/10.1186/1742-2094-8-92)
- 1016/j.jns.2012.04.008](https://doi.org/10.1016/j.jns.2012.04.008)
- 1016/j.neulet.2019.134524](https://doi.org/10.1016/j.neulet.2019.134524)
- 1016/j.autrev.2009.01.011](https://doi.org/10.1016/j.autrev.2009.01.011)
- 3389/fncel.2020.567543](https://doi.org/10.3389/fncel.2020.567543)
- 1016/j.cyto.2008.01.006](https://doi.org/10.1016/j.cyto.2008.01.006)
- 1038/nrn2297](https://doi.org/10.1038/nrn2297)
- 3389/fnagi.2020.615626](https://doi.org/10.3389/fnagi.2020.615626)
- Doyle et al. Toll-like receptor 4 contributes to microglial activation and amyloid pathology (2011)## See Also
-
- [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--';
- tooltip.style.border = '1px solid rgba(255,255,255,0.18)';
- tooltip.setAttribute('tabindex', '-1');
- tooltip.setAttribute('role', 'tooltip');
- tooltip.addEventListener('mouseenter', function() {
- if (hideTimer) {
- clearTimeout(hideTimer);
- hideTimer = null;
- }
- });
- tooltip.addEventListener('mouseleave', function() {
- tooltip.style.display = 'none';
- });
- document.body.appendChild(tooltip);
- return tooltip;
- }
- function placeTooltip(el, e) {
- var margin = 12;
- var left = e.clientX + margin;
- var top = e.clientY + margin;
- var maxLeft = window.innerWidth - el.offsetWidth - margin;
- var maxTop = window.innerHeight - el.offsetHeight - margin;
- if (left > maxLeft) left = Math.max(margin, maxLeft);
- if (top > maxTop) top = Math.max(margin, maxTop);
- el.style.left = left + 'px';
- el.style.top = top + 'px';
- }
- function renderTooltip(el, a) {
- var refNumber = a.getAttribute('data-ref-number') || '';
- var refText = a.getAttribute('data-ref-text') || a.getAttribute('title') || '';
- var refTitle = a.getAttribute('data-ref-title') || '';
- var refAuthors = a.getAttribute('data-ref-authors') || '';
- var refYear = a.getAttribute('data-ref-year') || '';
- var refJournal = a.getAttribute('data-ref-journal') || '';
- var refDoi = a.getAttribute('data-ref-doi') || '';
- var refUrl = a.getAttribute('data-ref-url') || '';
- while (el.firstChild) el.removeChild(el.firstChild);
- var header = document.createElement('div');
- header.style.fontWeight = '700';
- header.style.marginBottom = '4px';
- header.textContent = refNumber ? ('Reference [' + refNumber + ']') : 'Reference';
- el.appendChild(header);
- var body = document.createElement('div');
- if (refTitle) {
- var titleLine = document.createElement('div');
- titleLine.style.fontWeight = '600';
- titleLine.textContent = refTitle;
- body.appendChild(titleLine);
- }
- if (refAuthors || refYear || refJournal) {
- var meta = document.createElement('div');
- meta.style.marginTop = '4px';
- meta.style.opacity = '0.9';
- var parts = [];
- if (refAuthors) parts.push(refAuthors);
- if (refYear) parts.push(refYear);
- if (refJournal) parts.push(refJournal);
- meta.textContent = parts.join(' | ');
- body.appendChild(meta);
- }
- if (!refTitle && refText) {
- var fallbackText = document.createElement('div');
- fallbackText.textContent = refText;
- body.appendChild(fallbackText);
- }
- if (refDoi) {
- var doi = document.createElement('div');
- doi.style.marginTop = '4px';
- doi.style.fontFamily = 'monospace';
- doi.textContent = 'DOI: ' + refDoi;
- body.appendChild(doi);
- }
- el.appendChild(body);
- if (refUrl) {
- var link = document.createElement('a');
- link.href = refUrl;
- link.target = '_blank';
- link.rel = 'noopener noreferrer';
- link.textContent = 'Open source';
- link.style.display = 'inline-block';
- link.style.marginTop = '6px';
- link.style.color = '#9ecbff';
- link.style.textDecoration = 'underline';
- el.appendChild(link);
- }
- }
- function hideTooltipDelayed(delayMs) {
- if (!tooltip) return;
- if (hideTimer) clearTimeout(hideTimer);
- hideTimer = setTimeout(function() {
- if (tooltip) tooltip.style.display = 'none';
- activeAnchor = null;
- }, delayMs || 120);
- }
- function showTooltipForAnchor(a, e) {
- if (!a) return;
- if (hideTimer) {
- clearTimeout(hideTimer);
- hideTimer = null;
- }
- activeAnchor = a;
- var el = ensureTooltip();
- renderTooltip(el, a);
- el.style.display = 'block';
- if (e && typeof e.clientX === 'number' && typeof e.clientY === 'number') {
- placeTooltip(el, e);
- return;
- }
- var rect = a.getBoundingClientRect();
- placeTooltip(el, {
- clientX: rect.left + (rect.width / 2),
- clientY: rect.bottom
- });
- }
- document.addEventListener('mouseover', function(e) {
- var a = e.target.closest('a.ref-link');
- if (!a) return;
- showTooltipForAnchor(a, e);
- });
- document.addEventListener('mousemove', function(e) {
- if (!tooltip || tooltip.style.display !== 'block') return;
- placeTooltip(tooltip, e);
- });
- document.addEventListener('mouseout', function(e) {
- if (!tooltip) return;
- if (e.target.closest('a.ref-link')) {
- var to = e.relatedTarget;
- if (to && (to.closest && (to.closest('#nw-ref-tooltip') || to.closest('a.ref-link')))) {
- return;
- }
- hideTooltipDelayed(120);
- }
- });
- document.addEventListener('focusin', function(e) {
- var a = e.target.closest('a.ref-link');
- if (!a) return;
- showTooltipForAnchor(a, null);
- });
- document.addEventListener('focusout', function(e) {
- if (!tooltip) return;
- if (e.target.closest('a.ref-link')) {
- var to = e.relatedTarget;
- if (to && (to.closest && to.closest('#nw-ref-tooltip'))) {
- return;
- }
- hideTooltipDelayed(120);
- }
- });
- document.addEventListener('keydown', function(e) {
- if (e.key === 'Escape' && tooltip && tooltip.style.display === 'block') {
- tooltip.style.display = 'none';
- activeAnchor = null;
- }
- });
- })();
-